Center for the Study of Inflammatory Bowel Disease at Massachusetts General Hospital

马萨诸塞州总医院炎症性肠病研究中心

• 批准号: 9262326
• 负责人: Ramnik J Xavier
• 金额: $ 6.21万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-05-01 至 2016-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9262326
• 关键词: Advanced Development; Affect; Animal Model; Applied Research; Area; Back; Bacteria; Basic Science; Biology; Cell physiology; Cells; Cellular biology; Clinical; Collaborations; Communication; Communities; Complex; Crohn' s disease; Development; Diagnosis; Digestive System Disorders; Disease; Educational workshop; Engineering; Environment; Environmental Risk Factor; Epidemiologist; Epithelial; Epithelial Cells; Event; Fostering; Functional disorder; Funding; Gap Junctions; General Hospitals; Genetic; Genomics; Goals; Growth; Health; Human; Human Genetics; Human Microbiome; Immune; Immunologist; Immunology; Individual; Inflammatory; Inflammatory Bowel Diseases; Inflammatory disease of the intestine; Institutes; Institution; Lead; Massachusetts; Molecular; Morphology; Natural Immunity; Pathogenesis; Pathway interactions; Patients; Physiology; Productivity; Research; Research Personnel; Research Support; Resources; Route; Sampling; Scientist; Signal Transduction; System; Systems Biology; Technology; Therapeutic; Ulcerative Colitis; United States; adaptive immunity; base; disorder prevention; feeding; immune function; improved; insight; interest; intestinal homeostasis; member; microorganism interaction; programs; public health relevance; success; symposium; targeted treatment; technology development

 DESCRIPTION, OVERALL (provided by applicant): The overall goal of the Center for the Study of Inflammatory Bowel Disease (CSIBD) is to promote and facilitate research that will yield insight into the causes and pathogenesis of IBD and lead to improved therapeutic approaches. This overarching objective remains unchanged since the inception of the CSIBD in 1991 and has guided the Center through substantial growth and expansion. The research base is made up of 111 scientists with $48.7 million in digestive disease-related research support. Organizing these investigators by areas of focus, we divide the CSIBD into six central themes. Our goal of understanding human IBD is accomplished using six entry points: (1) genetics, (2) microbial interactions, (3) barrier function and epithelial cell biology, (4) innate and adaptive immunity, (5) therapeutics, and (6) systems biology and signal transduction. Clinicians, scientists, and engineers are embedded in each theme. A central priority of the CSIBD is to bring together researchers from these various approaches and to provide an intellectual nexus for these individuals to find common interests in understanding and treating IBD. This is accomplished through several routes. First, the five biomedical cores offer state-of-the-art resources and expertise from leaders in (1) Human Genetics and Microbiome, (2) Immunology, (3) Morphology, and (4) Genetic Animal Models. In addition to offering guidance and access to technologies, core directors serve as connection points between investigators, facilitating collaborations. Similarly, the (5) Clinical Core aids the community through access to thousands of patient samples while serving as a hub for interactions between clinicians and basic researchers. Operating independently of these cores, the close relationship between the CSIBD and the Broad Institute allows further access to cutting-edge technologies. The overall specific aims of the CSIBD are to (1) promote research in basic science areas relevant to better understanding of mucosal immune function and epithelial biology in IBD; (2) advance our understanding of gut pathophysiology by examining the gut as a "circuit": studying the core components of gut intra- and inter-cellular interactions that determine health and disease; (3) promote the study of the pathogenesis of IBD; (4) promote interactions among scientists exploring diverse fields that share relevance to IBD; (5) promote translational IBD research; (6) attract basic investigators to the study of IBD and mucosal immunology; and (7) provide an environment and mechanism to foster development of young investigators focused on IBD. A comprehensive Enrichment Program introduces new members to the IBD community and encourages face-to-face interactions between investigators from a range of fields. Attracting new members to the CSIBD and IBD research is also greatly facilitated through Pilot and Feasibility Program support, the success of which is reflected by 79% of recipients achieving external funding.

 总体描述（由申请人提供）：炎症性肠病研究中心 (CSIBD) 的总体目标是促进和促进研究，以深入了解 IBD 的病因和发病机制，并改进总体治疗方法。自 CSIBD 1991 年成立以来，其目标始终未变，并指导该中心实现大幅增长和扩张。该研究基地由 111 名科学家组成，耗资 4,870 万美元。我们按重点领域组织这些研究人员，将 CSIBD 分为六个中心主题，我们通过六个切入点来实现了解人类 IBD 的目标：(1) 遗传学，(2) 微生物相互作用，(3) CSIBD 的核心重点是屏障功能和上皮细胞生物学、(4) 先天性和适应性免疫、(5) 治疗学和 (6) 系统生物学和信号转导。聚集在一起首先，五个生物医学核心提供了来自领导者的最先进的资源和专业知识。在（1）人类遗传学和微生物组、（2）免疫学、（3）形态学和（4）遗传动物模型中，除了提供指导和技术获取之外，核心主任还充当研究人员之间的连接点，促进合作。这(5) 临床核心通过获取数千个患者样本来帮助社区，同时作为独立操作这些核心的民众和基础研究人员之间的互动中心，CSIBD 和布罗德研究所之间的密切关系允许进一步获取切割数据。 CSIBD 的总体具体目标是：(1) 促进与更好地了解 IBD 粘膜免疫功能和上皮生物学相关的基础科学领域的研究；(2) 通过检查肠道作为肠道病理生理学，增进我们对肠道病理生理学的理解。 “电路”：研究决定健康和疾病的肠道细胞内和细胞间相互作用的核心组成部分；（3）促进IBD发病机制的研究；（4）促进探索与IBD相关的不同领域的科学家之间的相互作用； (5) 促进 IBD 转化研究；(6) 吸引基础研究人员从事 IBD 和粘膜免疫学研究；(7) 提供环境和机制，促进专注于 IBD 的年轻研究人员的发展。这试点和可行性计划的支持也极大地促进了 IBD 社区以及来自各个领域的研究人员之间的面对面互动，79% 的接受者获得了外部支持，这反映了这一点的成功。资金。